Stunning successes and startling failures highlight 2006’s pharmaceutical industry. In this year-end retrospective report, we contemplate the importance of these developments and what they mean to the pharmaceutical industry. Additionaly, we asked industry experts for their opinions and integrated their commentary and analysis into this report.
Get the Answers You Need to Shape Your Strategy The winning technology of 2006 continues to be a major success for the drug industry; however, even successful and well-tried innovations can meet with disaster. Which technology has Decision Resources deemed most lucrative in 2006, and why is its potential for commercial success so great? Which particular agent proves that even the most promising technologies are not immune to the risks inherent in development? 2006 saw more development and deals within a group of products that is poised to dramatically change the way diseases are currently treated. What is this group of products, and what were the major business strategies and deals within this group in 2006? Competition between innovator companies and generics companies has never been higher as these groups battle to control drug markets; innovator companies continue to face unrelenting pressure from generics companies that want to invalidate drug patents and gain early market entry for their drugs. What were 2006’s developments on the generics front line? What strategies are innovator companies employing to ward off generics competition? A prominent strategy of the pharmaceutical industry—historically employed to bolster thin product pipelines and increase presence in more markets—continues in 2006. However, this strategy is threatening the productivity and innovation of the largest pharmaceutical manufacturers. What longstanding practice in the pharmaceutical industry is counterproductive in today’s industry? How may the recent decisions of one major company serve as a lesson?
